SCHEMBL7850414

SCHEMBL7850414

CCOP(=O)(CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)nc(OC)nc2cc1C1CC1)OCC

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EGFR P00533 16/20 0.49
▸ ERBB2 P04626 3/20 0.49
▸ ERBB4 Q15303 2/20 0.49
▸ HDAC3 O15379 4/20 0.44
▸ HDAC4 P56524 4/20 0.44
▸ HDAC1 Q13547 4/20 0.44
▸ HDAC7 Q8WUI4 4/20 0.44
▸ HDAC2 Q92769 4/20 0.44
▸ HDAC10 Q969S8 4/20 0.44
▸ HDAC11 Q96DB2 4/20 0.44
▸ HDAC8 Q9BY41 4/20 0.44
▸ HDAC6 Q9UBN7 4/20 0.44
▸ HDAC9 Q9UKV0 4/20 0.44
▸ HDAC5 Q9UQL6 4/20 0.44
▸ SRC P12931 2/20 0.42
▸ ERBB3 P21860 1/20 0.41
▸ DUS2 Q9NX74 1/20 0.41
▸ ABL1 P00519 1/20 0.41
▸ PDGFRB P09619 1/20 0.41
▸ PDGFRA P16234 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12525787 0.80 EGFR (0.57) EGFRERBB2ERBB4ABL1
SCHEMBL29737288 0.79 EGFR (0.59) EGFRERBB2ERBB4SRCERBB3
SCHEMBL27595565 0.78 RAF1 (0.46) EGFRERBB2ERBB4ERBB3DUS2
SCHEMBL3544316 0.78 EGFR (0.55) EGFRERBB2ERBB4SRCERBB3
SCHEMBL16986930 0.77 EGFR (0.56) EGFRERBB2ERBB4SRCERBB3
SCHEMBL1417948 0.77 EGFR (0.67) EGFRERBB2ERBB4HDAC3HDAC4
SCHEMBL6789229 0.76 EGFR (0.46) EGFRERBB2ERBB4PDGFRB
SCHEMBL27704368 0.76 EGFR (0.63) EGFRERBB2ERBB4SRC
SCHEMBL7852173 0.76 EGFR (0.59) EGFRERBB2ERBB4SRC
SCHEMBL5374589 0.76 EGFR (0.49) EGFRERBB2ERBB4SRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1341104-A 4-amino-quinazoline and quinoline derivatives having an inhibitory effect on signal transduction mediated by tyrosine kinases BOEHRINGER INGELHEIM PHARMA (DE) 2002-03-20 — — CN disclosed
EP-1157011-A1 4-AMINO- QUINAZOLINE AND QUINOLINE DERIVATIVES HAVING AN INHIBITORY EFFECT ON SIGNAL TRANSDUCTION MEDIATED BY TYROSINE KINASES Boehringer Ingelheim Pharma KG (DE) 2001-11-28 — — EP disclosed
WO-2000051991-A1 4-AMINO-QUINAZOLINE AND QUINOLINE DERIVATIVES HAVING AN INHIBITORY EFFECT ON SIGNAL TRANsSDUCTION MEDIATED BY TYROSINE KINASES BOEHRINGER INGELHEIM PHARMA KG (DE) 2000-09-08 — — WO disclosed
Send feedback